While infants with severe neutropenia seem to profit from a white blood cell reconstitution, no significant reduction of mortality was observed in newborns who received GM-CSF either given prophylactically or as a treatment of an already established systemic infection [11, 12]. This evidence concerns the gene CSF2 and Decreased total neutrophil count.